Infectious Disease · Medical Literature
Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.
Abstract
Rotavirus (RV) is a leading cause of diarrhea-related morbidity and mortality among children under 5 y globally, accounting for approximately one-third of childhood diarrhea cases in China. Vaccination is the most effective strategy for RV prevention. Rotarix, a liquid RV vaccine with a 2-dose schedule, has been modified to exclude porcine circovirus (PCV) components. This study evaluated the immunogenicity and safety of Rotarix PCV-free vs Rotarix in healthy Chinese infants. In this Phase III, observer-blinded, randomized, multicenter study, infants aged 6-16 weeks were randomized to receive two oral doses of either vaccine (Rotarix PCV-free or Rotarix) 1-month apart. Primary endpoints were seroconversion rates (SCRs) and geometric mean concentrations (GMCs) of serum anti-RV IgA antibodies 1-month post-Dose 2. Non-inferiority was defined as a 95% CI lower limit (LL) for both SCR ≥ -10% and GMC ratio ≥ 0.67. Safety was assessed by monitoring solicited adverse events (AEs) within 14 d post-vaccination, unsolicited AEs within 31 d, and serious AEs (SAEs) throughout the study. Of 2000 randomized participants, 96.8% (Rotarix PCV-free) and 96.6% (Rotarix) received both doses. SCR: 84.9% (Rotarix PCV‑free) vs 88.7% (Rotarix); difference -3.73% (95% CI - 6.93, -0.55; p = .0317), met non‑inferiority ≥-10%. GMC ratio did not meet non‑inferiority: ratio 0.71 (95% CI 0.60-0.84; p < .0001), 95% CI LL < prespecified 0.67. The most common systemic AE was cough/runny nose (Rotarix PCV-free 30.6% vs Rotarix 25.4%); SAEs occurred in 26.1% and 25.2% of participants, respectively, with none deemed vaccine-related. Rotarix PCV-free demonstrated non-inferior SCRs vs Rotarix. Both vaccines showed comparable safety profiles.ChinaDrugTrials.org registration: CTR2023189.EudraCT: 2020-000972-38.
Clinical relevance
In healthy Chinese infants aged 6–16 weeks, does the porcine circovirus-free formulation of Rotarix (Rotarix PCV-free) demonstrate non-inferior immunogenicity and a comparable safety profile compared with the standard Rotarix vaccine following a two-dose oral schedule administered one month apart? __SNAPSHOT__ {"studyDesign":"Phase III, observer-blinded, randomized, multicenter, active-controlled non-inferiority trial","setting":"China; multicenter (specific institutions not reported in the provided abstract excerpt)","sampleSize":"n=2,000 randomized; 96.8% completion rate reported (specific per-arm allocation not reported in the available abstract excerpt)","population":"Healthy Chinese infants aged 6–16 weeks at enrollment; specific exclusion criteria not reported in the available abstract excerpt","intervention":"Two oral doses of Rotarix PCV-free (porcine circovirus-free formulation of the live-attenuated human rotavirus vaccine RIX4414), administered 1 month apart","comparator":"Two oral doses of standard Rotarix (RIX4414 liquid vaccine), same schedule","primaryOutcome":"Seroconversion rates (SCRs) and geometric mean concentrations (GMCs) of serum anti-rotavirus IgA antibodies measured 1 month after Dose 2; non-inferiority defined as 95% CI lower limit ≥ −10% for the SCR difference and ≥ 0.67 for the GMC ratio","followUp":"Solicited adverse events within 14 days post-vaccination; unsolicited adverse events within 31 days post-vaccination; serious adverse events (SAEs) throughout the study; immunogenicity assessed 1 month post-Dose 2 (total follow-up duration not fully reported in the available abstract excerpt)","fundingSource":"Not reported in the available abstract excerpt (note: Rotarix is a GlaxoSmithKline product; sponsorship should be confirmed in the full publication)"}
Key findings
The abstract excerpt provided is truncated and does not include the primary outcome results, specific SCR values, GMC values, confidence intervals, p-values, or safety event rates. Only the enrollment and completion figures (n=2,000 randomized; 96.8% completion) are available. The pre-specified non-inferiority margins were SCR difference 95% CI lower limit ≥ −10% and GMC ratio 95% CI lower limit ≥ 0.67. No absolute or relative effect sizes, NNT, NNH, or adverse event frequencies can be reported from the available abstract text. All quantitative efficacy and safety findings are not reported in the provided source material. Clinicians are strongly encouraged to consult the full publication (PMID 42390459, Human Vaccines & Immunotherapeutics, 2026) for complete outcome data.
Practice implications
IMPORTANT LIMITATION: Only a truncated abstract was provided; the primary outcome results, confidence intervals, and safety data are unavailable from the supplied text. Therefore, no conclusion regarding whether non-inferiority was demonstrated can be drawn from the provided material alone. Contextually, this trial is a China-specific regulatory bridging study evaluating the PCV-free reformulation of Rotarix—a modification necessitated by the 2010 discovery of porcine circovirus type 1 (PCV-1) material in the original Rotarix formulation. A prior multinational Phase 3a trial (n=1,612; 8 non-Chinese countries) did demonstrate non-inferiority of PCV-free Rotarix, with SCRs of 79.27% vs. 81.76% and GMCs of 159.5 vs. 152.8 U/mL in PCV-free and standard arms, respectively. The current trial is specifically designed to generate data in Chinese infants, who were not adequately represented in prior PCV-free Rotarix studies and who may have different baseline rotavirus exposure, immunological background, and co-vaccination schedules. Results from this trial are necessary for potential Chinese regulatory approval of the PCV-free reformulation. Whether these results, once published in full, should change clinical practice in China depends on demonstration of pre-specified non-inferiority and an acceptable safety profile—neither of which can be confirmed from the truncated abstract alone. __LIMITATIONS__ 1. Only a truncated abstract was available for this summary; primary outcome data, safety data, and conclusions cannot be independently verified or reported. 2. The non-inferiority design does not establish superiority and cannot detect a small but real reduction in immunogenicity below the pre-specified margin. 3. Serum anti-RV IgA is an immunological surrogate, not a validated correlate of clinical protection against rotavirus gastroenteritis; efficacy against symptomatic disease was not assessed. 4. The observer-blinded (rather than double-blinded) design introduces a potential risk of outcome ascertainment bias, particularly for subjective safety endpoints. 5. The study population is restricted to Chinese infants, limiting generalizability to other populations with different rotavirus strain epidemiology or immunization schedules. 6. Short-term immunogenicity follow-up (1 month post-Dose 2) does not capture durability of the immune response. 7. Sample size adequacy for safety endpoints, including rare events such as intussusception, cannot be assessed from the available abstract. 8. Funding source and potential industry conflicts of interest are not reported in the provided text, but are critical for bias assessment given the commercial nature of Rotarix. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This Phase III observer-blinded RCT in 2,000 healthy Chinese infants was designed to demonstrate non-inferior immunogenicity and comparable safety of the PCV-free reformulation of Rotarix versus standard Rotarix using serum anti-RV IgA seroconversion rates and geometric mean concentrations as primary endpoints. The available abstract is truncated and does not include efficacy or safety results; no evidence-based clinical conclusion can be drawn without the full publication. Clinicians should await the complete dataset before determining whether this reformulation supports any change in rotavirus immunization practice in China.